Hefei T-Gong Biotechnology

Hefei T-Gong Biotechnology is a clinical-stage biopharmaceutical company based in China that specializes in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies. Founded by industry veteran Dr. Lin Yang, the company focuses on overcoming the traditional barriers of cell therapy, particularly its limited efficacy in solid tumors and issues with cell persistence. T-Gong utilizes proprietary genetic engineering technologies to create "logic-gated" and enhanced CAR-T cells designed for superior safety and potency. Their pipeline includes candidates targeting well-validated hematological markers as well as novel targets for difficult-to-treat solid malignancies. The company aims to streamline the manufacturing process to make advanced immunotherapies more accessible to a broader patient population.